MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
Science translational medicine (Impact Factor: 14.41). 06/2011; 3(85):85ra48. DOI: 10.1126/scitranslmed.3002336
Source: PubMed

ABSTRACT Oil-in-water adjuvants have been shown to improve immune responses against pandemic influenza vaccines as well as reduce the effective vaccine dose, increasing the number of doses available to meet global vaccine demand. Here, we use genome fragment phage display libraries and surface plasmon resonance to elucidate the effects of MF59 on the quantity, diversity, specificity, and affinity maturation of human antibody responses to the swine-origin H1N1 vaccine in different age groups. In adults and children, MF59 selectively enhanced antibody responses to the hemagglutinin 1 (HA1) globular head relative to the more conserved HA2 domain in terms of increased antibody titers as well as a more diverse antibody epitope repertoire. Antibody affinity, as inferred by greatly diminished (≥10-fold) off-rate constants, was significantly increased in toddlers and children who received the MF59-adjuvanted vaccine. Moreover, MF59 also improved antibody affinity maturation after each sequential vaccination against avian H5N1 in adults. For both pandemic influenza vaccines, there was a close correlation between serum antibody affinity and virus-neutralizing capacity. Thus, MF59 quantitatively and qualitatively enhances functional antibody responses to HA-based vaccines by improving both epitope breadth and binding affinity, demonstrating the added value of such adjuvants for influenza vaccines.

Download full-text


Available from: Jonathan W Yewdell, Aug 14, 2015
  • Source
    • "MF59 acts locally by activating monocytes, macrophages and dendritic cells, which release a mixture of cytokines attracting phagocytic cells to the injection site, resulting in more efficient antigen-transport to the lymph nodes [18] [19]. MF59 has also been shown to enhance the immune response by increasing the binding strength of antibody to the influenza virus [16] [17] Influenza vaccines containing MF59 have also consistently demonstrated an established safety profile [20] [21] [22] [23]. The MF59-adjuvanted seasonal influenza vaccine, Fluad ® , is recommended in numerous countries for adults over the age of 65, but further research is particularly necessary to assess the effectiveness and safety of inclusion of MF59 adjuvant in seasonal vaccines for children. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Non-adjuvanted seasonal influenza vaccines show only modest efficacy in young children. This study compared the immunogenicity, reactogenicity and safety of the MF59 (R)-adjuvanted trivalent subunit vaccine (aTIV) with two non-adjuvanted trivalent vaccines, TIV-1, the non-adjuvanted version of aTIV, and TIV-2, a split virion vaccine. Methods: 6078 children received two doses of aTIV (n = 3125), TIV-1 (n = 1479), or TIV-2 (n = 1474) four weeks apart (Days 1 and 29). Children aged 6 to <36 months and 36 to <72 months received 0.25 mL and 0.50 mL doses, respectively. Immunogenicity was assessed by hemagglutination inhibition (HI) assay (n = 2435) on Days 1, 29, 50 and 209. Safety was assessed up to Day 394. Results: After the second vaccination (Day 50), the aTIV group showed significantly higher geometric mean HI titers and seroconversion rates than the TIV-1 or TIV-2 groups against all homologous and heterologous strains. The difference was enhanced at HI titers >= 110. aTIV elicited a faster, more persistent antibody response, with significantly higher titers in the aTIV group after one vaccination (Day 29) and after six months (Day 209) than in either TIV group. aTIV was more reactogenic than were TIV-1 and TIV-2 but rates of severe adverse events were very low for all three vaccines. Conclusion: In infants and young children, the MF59-adjuvanted vaccine induced substantially faster (after one dose), higher, persistent HI titers than the non-adjuvanted vaccines, with consistently higher seroprotection rates at increased threshold HI titers.
    Vaccine 09/2014; 32(46). DOI:10.1016/j.vaccine.2014.08.068 · 3.49 Impact Factor
  • Source
    • "Thus far, analyses of humoral immunity to the HPV vaccines have been limited to assessment of VLP binding titers and neutralizing activity, and little is known about antibody avidity following HPV vaccination. While the contribution of avidity maturation to protection against viral infections in general is still not well defined and controversial [8] [9] [10], the assessment of antibody avidity may provide a more complete view of the quality and function of systemic antibodies induced by vaccination. Lastly, there is little known about the effects of a type-specific cervical HPV infection at the time of vaccination on vaccine-induced antibody responses and duration of immunity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: We previously demonstrated that Cervarix(®) elicits antibody responses against vaccine-related types for which clinical efficacy was demonstrated (HPV-31 and -45). Here, we evaluated the kinetics of neutralization titers and avidity of Cervarix(®)-induced antibodies up to 36 months of follow-up in unexposed and HPV infected women. METHODS: A subset of women who participated in the Cost Rica HPV-16/18 Vaccine Trial had pre- and post-vaccination sera tested for antibody responses to HPV-16, -18, -31, -45, and -58 using a pseudovirion-based neutralization assay, and HPV-16 antibody avidity using an HPV-16 L1 VLP (virus-like particle)-based ELISA developed in our laboratory. RESULTS: In uninfected women, neutralizing antibody titers did not reach significance until after the 3rd dose for HPV-31 (month 12, p=0.009) and HPV-45 (month 12, p=0.003), but then persisted up to month 36 (HPV-31, p=0.01; HPV-45, p=0.002). Individuals infected with HPV-16 or HPV-31 at enrollment developed a significantly higher median antibody response to the corresponding HPV type after one dose, but there was not a difference between median titers after three doses compared to the HPV negative group. Median HPV-16 antibody avidity and titer increased over time up to month 12; however, the HPV-16 avidity did not correlate well with HPV-16 neutralizing antibody titers at each time point examined, except for month 6. The median avidity levels were higher in HPV-16 infected women at month 1 (p=0.04) and lower in HPV-16 infected women at month 12 (p=0.006) compared to the HPV negative women. CONCLUSIONS: The persistence of cross-neutralization titers at month 36 suggests cross-reactive antibody responses are likely to persist long-term and are not influenced by infection status at enrollment. However, the weak correlation between avidity and neutralization titers emphasizes the need for examining avidity in efficacy studies to determine if high avidity antibodies play a critical role in protection against infection.
    Vaccine 10/2012; 31(1). DOI:10.1016/j.vaccine.2012.10.067 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Influenza is an important public health issue, especially with the aging of the population, since the most serious consequences of the illness affect the elderly. Between 1979 and 2001, approximately 41000 annual deaths have been attributed to influenza in the United States (Dushoff, 2005). Annual vaccination is a key strategy employed to combat this illness, and while it is very effective in healthy young adults, it is much less successful in the elderly. The impaired immune system with aging may contribute to this diminished ability of the vaccine to afford protection. Strategies to improve vaccine efficacy, particularly for the aged population, are necessary. One potential strategy is the inclusion of adjuvants in the vaccine formulations to enhance the immune response. Adjuvants have been shown to improve antibody production, allow dose-sparing, and potentially increase cross-reactivity. These benefits are important in combating both seasonal influenza and pandemic influenza, as current seasonal vaccine effectiveness depends on close matching to the circulating virus, and fast production of pandemic vaccines are key to their effectiveness. While much is still unknown about adjuvants, especially their mechanisms of action, their potential at improving the efficacy of influenza vaccines has been well recognized, particularly in the elderly.
    06/2012; 7(3). DOI:10.1007/s11515-012-1221-3
Show more